Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An Alzheimer's disease that is characterized by an associated with variation in the region 8p12-q22.
Clinical Trials1 registered
Diagnosis
Biomarker and diagnostic research for Alzheimer disease 12 has been reported in the published literature.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
1 clinical trial registered. Interventions under study include medical devices. Pipeline includes 1 NA. Research is primarily industry-sponsored.
199 publications have been identified in PubMed for Alzheimer disease 12. Kisho has analyzed 85 by research type. Research spans Basic Science / Preclinical (46%), Review / Meta-Analysis (19%), and Epidemiology / Natural History (18%).
Research Type
Count
% of Total
Laboratory research
39
46%
Data assembled from 4 of 12 sources · Last updated Nov 4, 2026, 6:12 AM UTC
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
→Are any of the 1 active clinical trial a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?
FAQ
Frequently Asked Questions
Common questions about Alzheimer disease 12
Alzheimer disease 12 is a form of Alzheimer’s disease that has been linked to a genetic variation found in the region 8p12-q22. This variation involves the AD12 gene, which is considered important in understanding how the disease develops in people with this condition.
Research into Alzheimer disease 12 continues to explore the specific role of this genetic change and its impact on brain function, adding to our general understanding of Alzheimer’s disease. The available information highlights the importance of genetic factors in the development of this rare form of Alzheimer’s.
Information about symptoms is currently limited for this condition.
Alzheimer disease 12 is linked to a variation in the region 8p12-q22, which involves the AD12 gene. This genetic change is thought to play a role in the development of the condition. More research is needed to fully understand all factors contributing to the disease.
Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.
communication and shared decision making for anti amyloid therapy in early alzheimer s disease an exploratory qualitative study of real world audio recorded clinical encounters
Yaqrit is a clinical-stage biotechnology company developing treatments in this area. 🤝 London-based Trigeminal Neuralgia Institute has launched to improve care for patients. The Trigeminal Neuralgia Institute has launched following a fundraising and launch event.. The UK charity, registered number 1204273, aims to improve understanding of trigeminal neuralgia and ensure every patient can access diagnosis and multidisciplinary care. Trigeminal neuralgia is a rare... Yaqrit is a clinical-stage biotechnology company developing treatments in this area. 🤝 London-based Trigeminal Neuralgia Institute has launched to improve care for patients. The Trigeminal Neuralgia Institute has launched following a fundraising and launch event.. The UK charity, registered number 1204273, aims to improve understanding of trigeminal neuralgia and ensure every patient can access diagnosis and multidisciplinary care. Trigeminal neuralgia is a rare, long-term condition causing sudden, recurring episodes of facial pain, often triggered by light touch, and is estimated to affect around 45,000 people in the UK. In a mouse model of HER2+/FAP+ gastric tumours progressed after Enhertu, AVA6103 showed superior disease control. First efficacy data are expected in H1 2027. 📖 London-based Parkwalk has revealed £1.56bn invested into UK spinouts in H1 2026. Parkwalk, in partnership with IP Group and Beauhurst, has published its Equity Investment into Spinouts 2026 report. The UK Dementia Research Institute and Alzheimer’s Research UK have launched AD-SMART, a national trial that could cut years from testing Alzheimer’s treatments. It runs in partnership with the National Institute for Health and Care Research, the Medical Research Council and Health Data Research UK, with ongoing funding from the UK government. The Gatsby Charitable Foundation and Wellcome Trust have renewed funding for neuroscience and AI research at UCL, committing £112.5 million over five years. The money will sustain the Gatsby Computational Neuroscience Unit and the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, which work together in a shared building to study how brains and machines compute, learn and behave. The renewal continues a partnership dating to 1998, when Lord Sainsbury funded the Gatsby Unit as one of the first places to combine computational neuroscience and machine learning.
Image http www abnewswire com pressreleases wp content uploads 2026 10 2026 A completed acquisition an AI platform launch cancer immunotherapy research and laboratory milestones highlight five companies pursuing different paths toward growth DALLAS Texas October 13 2026 Alaunos Therapeutics ... Press release - ABNewswire - 5 Biotech Stocks' TCRT, IGC, PDSB, PFAI, Acquisition, Alzheimer's, Cardio and Cancer Research Milestones - published on openPR.com DALLAS, Texas, October 13, 2026 Alaunos Therapeutics (NASDAQ: TCRT), IGC Pharma (NYSE American: IGC), PDS Biotechnology (NASDAQ: PDSB), Pinnacle Food Group (NASDAQ: PFAI) and VivoSim Labs (NASDAQ: VIVS) are advancing initiatives across cardiopulmonary disease, Alzheimer's care, cancer immunotherapy, recombinant protein production and predictive toxicology. Alaunos Therapeutics: Velaris Acquisition Expands Cardiopulmonary Pipeline Alaunos Therapeutics, Inc. (NASDAQ: TCRT) announced the completion of its acquisition of Velaris Therapeutics, Inc., a privately held biotechnology company developing potential treatments for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The launch expands its AI strategy, while deployment agreements, validation and revenue generation remain developments to watch. PDS Biotechnology: Cancer Research Adds Clinical and Peer-Reviewed Visibility PDS Biotechnology Corporation (NASDAQ: PDSB) announced an upcoming virtual expert event featuring Jonathan M.
